European and US drug companies represented respectively by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) recently issued joint Principles for Responsible Clinical Trial Data Sharing. This will allow independent researchers to scrutinize the results of drug companies’ clinical studies. In reaction though, drug companies are resisting efforts to make these data public or available to competitors. This is becoming a huge issue internationally, and has sparked a global debate discussed upon in very recent articles by the New York Times and the Financial Times.
Being a strong proponent of public scrutiny of health research data and results, but on the other hand also being conscious that public health needs to be balanced with commercial confidentiality, the Life Sciences and Health Care Research Platform of Vlerick Business School is proud to host an urgent high-level public Roundtable on this topic in its Brussels’ campus August 27, 13:00 – 17:00 titled ‘A Roadmap for Sharing Clinical Trial Data’
to this timely event is now open.